Table 2 Evolution of therapy in patient 2
Regimen | Duration of therapy (mo) | Best response | Reason of stopping |
|---|---|---|---|
Bortezomib/lenalidomide/dexamethasone (VRd) | 1 (May 2017) | NA | Allergic reaction |
Bortezomib/thalidomide/dexamethasone (VTd) | 4 (Jun–Aug 2017) | CR | Auto-HSCT |
Thalidomide maintenance | 8 (Feb–Sep 2018) | VGPR | PD |
Carfilzomib/dexamethasone (Kd) | 2 (Dec 2018–Jan 2019) | NA | Respiratory failure |
Daratumumab/pomalidomide/dexamethasone (DPd) | 2 (Feb–Mar 2019) | PD | PD |
Venetoclax/carfilzomib/dexamethasone (VenKd) | 3 (Apr–Jun 2019) | Improvement of plasmacytoma | Plasma cell leukemia |